<DOC>
	<DOC>NCT00206102</DOC>
	<brief_summary>This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic potential.</brief_summary>
	<brief_title>A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Men and women age 18 to 65 Both Eyes present with lenses intact (no previous cataract extractions) Stable place of residency History of corneal surgery Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or both eyes Previous participation in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
</DOC>